International Federation of Psoriasis Associations (IFPA), 2024

Bimekizumab simultaneous skin and nail clearance in patients with psoriasis: Assessing comparative efficacy in four phase 3/3b studies

Merola F. Joseph, Warren B. Richard, Thaci Diamant, et al.

Bimekizumab efficacy by body region in plaque psoriasis: Comparative analyses from four phase 3/3b studies

Savage J. Laura, Pinter Andreas, Crowley Jeffrey, et al.

Bimekizumab treatment in psoriasis patients: A mechanistic understanding of the durable clinical response

Cutcutache Ioana, Skelton Andrew, Kolivras Athanassios, et al.

Bimekizumab long-term efficacy in patients with plaque psoriasis from BE BRIGHT: Mean percentage improvement in clinical outcomes over 4 years

Gerdes Sascha, Costanzo Antonio, Fernandez-Peñas Pablo, et al.

Bimekizumab efficacy in moderate to severe plaque psoriasis: Improvements in fatigue observed in two phase 3 studies

Alice B Gottlieb, Augustin Matthias, Lambert Jo, et al.

Bimekizumab reduced psoriatic arthritis impact in patients with psoriasis: Up to 2-year results from two phase 3 studies

Gossec Laure, Gladman D. Dafna, Gisondi Paolo, et al.

Bimekizumab efficacy and safety in patients with psoriatic arthritis and psoriasis: Up to 2-year results from two phase 3 studies

Thaci Diamant, Alice B Gottlieb, Akihiko Asahina, et al.